PWPS
EGRX

Pinnacle Wealth Planning Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-152
Closed -$7K – 2060
2020
Q4 		$7K Buy
+152
New +$7.11K ﹤0.01% 1557

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pinnacle Wealth Planning Services's EGRX Position: Q1 2021 in Review

Pinnacle Wealth Planning Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 152 shares — an estimated $7K sold.

Pinnacle Wealth Planning Services first reported a position in EGRX in Q4 2020 and held it in 1 quarter. The position peaked at $7K in Q4 2020. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

  • Pinnacle Wealth Planning Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Pinnacle Wealth Planning Services sold 152 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $7K.
  • Pinnacle Wealth Planning Services first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Pinnacle Wealth Planning Services's Eagle Pharmaceuticals, Inc. position peaked at $7K in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2021, filed 29 Apr 2021.